Towards Precision Medicine For Non-small Cell Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$463,652.00
Summary
Better outcomes are needed for lung cancer, a disease that accounts for more cancer-related deaths than any other cancer in Australia or worldwide. My goals are to 1) develop and evaluate in clinical trials targeted therapies and immunotherapies and 2) identify clinically relevant blood and tissue based biomarkers for lung cancer patients. This combination of clinical and translational research will change practice and improve outcomes by delivering precision medicine for lung cancer patients.
Cyclin E1 As A Therapeutic Target In Women With High-grade Serous Cancer And Primary Treatment Failure
Funder
National Health and Medical Research Council
Funding Amount
$644,170.00
Summary
Ovarian cancer is the 5th most common cancer in women and the most lethal gynaecologic malignancy. We found tumours with extra copies of the CyclinE1 gene (CCNE1) are less likely to respond to standard treatment, and show reliance on its activity. Therefore, targeting CCNE1 may be a novel treatment strategy for these cancers. We will perform preclinical studies with therapeutic inhibitors towards the CCNE1 pathway and further explore the underlying biology of tumours with CCNE1 amplification.
The Transcription Factor ZNF652: Deciphering Its Role In Breast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$342,996.00
Summary
From our continuing research we have shown a protein called ZNF652 is involved in cancer. This proposal focuses on the role of this gene in the spread of cancer within the breast and to other organs. We will determine its role in a process where a cancer cell changes its characteristics to make it more likely to spread to other tissues. Our preliminary results suggest ZNF652 could be a marker that will predict poor prognosis. This proposal will further investigate this finding.